Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242115701 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Leszek Krolicki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, Medical University of Warsaw, 02-091 Warsaw, Poland. Hauptthemen laut MEDLINE: Oligodendroglioma, Glioma, Astrocytoma, Glioblastoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, European Commission.
Abstract (Originalsprache)
The median survival time has been reported to vary between 5 and 8 years in low-grade (WHO grade 2) astrocytoma, and between 10 and 15 years for grade 2 oligodendroglioma. Targeted alpha therapy (TAT), using the modified peptide vector [213Bi]Bi/[225Ac]Ac-DOTA-substance P, has been developed to treat glioblastoma (GBM), a prevalent malignant brain tumor. In order to assess the risk of late neurotoxicity, assuming that reduced tumor cell proliferation and invasion should directly translate into good responses in low-grade gliomas (LGGs), a limited number of patients with diffuse invasive astrocytoma (n = 8) and oligodendroglioma (n = 3) were offered TAT. In two oligodendroglioma patients, TAT was applied as a second-line treatment for tumor progression, 10 years after targeted beta therapy using [90Y]Y-DOTA-substance P. The radiopharmaceutical was locally injected directly into the tumor via a stereotactic insertion of a capsule–catheter system. The activity used for radiolabeling was 2–2.5 GBq of Bismuth-213 and 17 to 35 MBq of Actinium-225, mostly applied in a single fraction. The recurrence-free survival times were in the range of 2 to 16 years (median 11 years) in low-grade astrocytoma (n = 8), in which TAT was administered following a biopsy or tumor debulking. Regarding oligodendroglioma, the recurrence-free survival time was 24 years in the first case treated, and 4 and 5 years in the two second-line cases. In conclusion, TAT leads to long-term tumor control in the majority of patients with LGG, and recurrence has so far not manifested in patients with low-grade (grade 2) astrocytomas who received TAT as a first-line therapy. We conclude that targeted alpha therapy has the potential to become a new treatment paradigm in LGG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Department, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Neurosurgery Department, University Hospital Basel, 4031 Basel, Switzerland.
- Department of Neurology, Inselspital, University Hospital Bern, 3010 Bern, Switzerland.
- Department of Neurosurgery, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland.
- European Commission, Joint Research Centre (JRC), 76125 Karlsruhe, Germany.
- Nuclear Medicine and Radiochemistry, University Hospital Basel, 4031 Basel, Switzerland.
ORCID-Profile: Jolanta Kunikowska
Förderung
- Swiss National Science Foundation
- European Commission
Zitieren
APA
Krolicki, L., Kunikowska, J., Cordier, D., Slavova, N., Koziara, H., Bruchertseifer, F., Maecke, H. R., Morgenstern, A., & Merlo, A. (2023). Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242115701
Vancouver
Krolicki L, Kunikowska J, Cordier D, Slavova N, Koziara H, Bruchertseifer F, et al. Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242115701
BibTeX
@article{Krolicki2023,
author = {Krolicki, Leszek and Kunikowska, Jolanta and Cordier, Dominik and Slavova, Nedelina and Koziara, Henryk and Bruchertseifer, Frank and Maecke, Helmut R and Morgenstern, Alfred and Merlo, Adrian},
title = {Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242115701}
}
EUVIMED